Increased risk of angioedema w/ ACE inhibitors. Higher frequency of adverse events eg, hypotension, hyperkalemia & decreased renal function w/ aliskiren. Not to be co-administered w/ angiotensin receptor blocker. Increased Cmax
of atorvastatin. Greater BP reduction w/ sildenafil or another PDE-5 inhibitor. Increased serum K & serum creatinine w/ K-sparing diuretics (eg, triamterene, amiloride), mineralocorticoid antagonists (eg, spironolactone, eplerenone), K supplements, or salt substitutes containing K. Increased risk of worsening of renal function w/ NSAIDs. Reversible increases in serum lithium. Reduce Cmax
& AUC of furosemide & metformin. May increase systemic exposure to sacubitrilat or valsartan w/ inhibitors of OATP1B1, OATP1B3, OAT3 (eg, rifampin, cyclosporine), OAT1 (eg, tenofovir, cidofovir) or MRP2 (eg, ritonavir).